PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding PMV Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 93 | 1 | 74 | −18 |
| Shares | 40.5M | 1.16M | 39.0M | −306.7K (−0.8%) |
| Value | $65.6M | $1.88M | $58.2M | −$5.56M (−8.7%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,144,797 | $1.71M | 0.00% |
| Panagora Asset Management Inc | 89,631 | $133.6K | 0.00% |
| Virtu Financial LLC | 28,146 | $42.0K | 0.00% |
| Amundi | 26,182 | $38.9K | 0.00% |
| Advisor Group Holdings, Inc. | 1,320 | $1.97K | 0.00% |
Sold out (23)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Opaleye Management Inc. | 475,000 | $769.5K |
| Ghost Tree Capital, LLC | 375,000 | $607.5K |
| Exome Asset Management LLC | 358,400 | $580.6K |
| Charles Schwab Investment Management Inc | 178,592 | $289.3K |
| AQR Capital Management LLC | 118,917 | $192.6K |
| Centiva Capital, LP | 76,963 | $124.7K |
| Fishman Jay A Ltd | 70,000 | $113.4K |
| Man Group plc | 62,048 | $100.5K |
| American Century Companies Inc | 50,241 | $81.4K |
| Paloma Partners Management Co | 35,069 | $56.8K |
| Y-Intercept (Hong Kong) Ltd | 31,749 | $51.4K |
| State of Wyoming | 25,022 | $40.5K |
| Rhumbline Advisers | 23,035 | $37.3K |
| Mirae Asset Global ETFs Holdings Ltd. | 21,151 | $34.3K |
| Algert Global LLC | 15,130 | $24.5K |
| Point72 (DIFC) Ltd | 14,545 | $23.6K |
| Jump Financial, LLC | 11,873 | $19.2K |
| HRT Financial LP | 12,014 | $19.0K |
| Russell Investments Group, Ltd. | 4,711 | $7.63K |
| Macquarie Group Ltd | 2,077 | $3.37K |
| Capital Advisors, Ltd. LLC | 322 | $1.00K |
| New York State Common Retirement Fund | 341 | $552 |
| CWM, LLC | 230 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,162,193 | $1.88M |